top of page

Minimized Assay Interference

Innovative NOVEOS® assay design helps minimize the impact of common interferences, supporting accurate and reliable allergy testing

Reducing the Risk of False Negative Results

The NOVEOS® indirect assay design avoids competition for binding sites by patient allergen-specific antibodies and endogenous biotin in a patient sample.

Reducing the Risk of False Positive Results

NOVEOS® utilizes an innovative microparticle-based assay design without cellulose-based solid phases, helping minimize the potential for Cross-reactive Carbohydrate Determinant (CCD)-related interference associated with cellulose-containing materials. The low sample volume requirement may reduce the impact of serum-derived interfering substances. The microparticle technology provides increased reactive surface area, supporting high analytical sensitivity.

bottom of page